The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Respiratory Disease Vaccine Market From 2026 To 2030?
The respiratory disease vaccine market size has experienced marginal growth in recent years. It is anticipated to increase from $70.03 billion in 2025 to $71.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 1.9%. This past growth can be attributed to the high prevalence of respiratory infections, the limited availability of effective vaccines, government immunization initiatives, advancements in monoclonal antibody research, and rising awareness about respiratory health.
The respiratory disease vaccine market size is anticipated to show consistent expansion in the coming years, projected to reach $81 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 3.2%. This growth over the forecast period is attributable to an increased demand for universal vaccines, technological progress in mRNA and viral vector vaccines, the expansion of cold-chain infrastructure, a rise in public-private partnerships for vaccine distribution, and a focus on pandemic preparedness and rapid response. Significant trends during this period encompass the development of next-generation respiratory vaccines, an amplified focus on pediatric and geriatric immunization, the broadening of immunization programs in emerging markets, the emergence of combination vaccines for multi-pathogen protection, and the adoption of rapid vaccine development and distribution platforms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
What Are The Main Drivers Accelerating The Growth Of The Respiratory Disease Vaccine Market?
The increasing occurrence of tuberculosis (TB) is anticipated to drive expansion in the respiratory disease vaccine market going forward. Tuberculosis is an infectious respiratory illness caused by Mycobacterium tuberculosis, primarily affecting the lungs and posing a significant global health threat. The growing number of TB cases is influenced by factors such as weakened healthcare systems, delays in diagnosis, and broader transmission patterns, all contributing to an increased disease burden. Respiratory disease vaccines play a vital role in mitigating TB-related risks by reducing infection rates, limiting transmission, and supporting global prevention strategies. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, the escalating incidence of tuberculosis is fueling the growth of the respiratory disease vaccine market.
What Are The Major Segment Categories Within The Respiratory Disease Vaccine Market?
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine
What Trends Are Influencing The Future Of The Respiratory Disease Vaccine Market?
Leading companies within the respiratory disease vaccine market are prioritizing the creation of innovative solutions aimed at improving their effectiveness and delivering enhanced methods for preventing and treating respiratory infections. For example, in May 2023, Pfizer Inc., a pharmaceutical company based in the US, secured Food and Drug Administration (FDA) authorization for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is intended for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine, consisting of a pair of preF proteins specifically engineered to maximize immunity against RSV A and B varieties, and its safety and efficacy have been confirmed through clinical trials.
Which Industry Players Are Present In The Respiratory Disease Vaccine Market?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
Access The Complete Respiratory Disease Vaccine Market Report:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Which Region Has The Strongest Presence In The Respiratory Disease Vaccine Market?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Respiratory Disease Vaccine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2026, By The Business Research Company
Respiratory Disease Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Influenza Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model